HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)
Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
* Spark Violet™ 423 has a maximum excitation of 400 nm and a maximum emission of 415 nm.
References
Brodsky F. 1984. Immunogenetics 19:179.
Robbins P, et al. 1987. Human Immunol. 18:301.
Stites D, et al. 1986. Clin. Immunol. Immunopathol. 38:161.
Warnke R, et al. 1980. J. Histochem. Cytochem. 28:771. (IHC)
Engleman E, et al. 1981. P. Natl. Acad. Sci. USA 78:1791. (IHC)
Zipf T, et al. 1981. Cancer Res. 41:4786.
Goodier M, et al. 2000. J. Immunol. 165:139. (Depletion)
Esser M, et al. 2001. J. Virol. 75:6173. (IP, WB)
Kalka-Moll WM, et al. 2002. J. Immunol. 169:6149. (Block)
Wang RF, et al. 1999. Science 284:1351. (Block)
Zaba LC, et al. 2007. J. Exp. Med. 204:3183. PubMed
Fujita H, et al. 2009. P. Natl. Acad. Sci. USA 106:21795. PubMed
Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
Goncalves RM, et al. 2010. Infect. Immun. 78:4763. PubMed
Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
Stein R, et al. 2011. Leuk. Lymphoma 52:273.
Galkowska H, et al. 1996. Vet. Immunol. Immunopathol. 53:329.
Moro M, et al. 2005. BMC Immunol. 6:24.
Lauterbach N, et al. 2014. Mol Immunol. 59:19. PubMed